Uploaded January 2026 | Updated September 2026, 2 weeks ago
Is AI in drug discovery a wasted effort?
In this excerpt from Gradient Dissent, Martin Shkreli co-founder of DL Software, shares his controversial take on why he believes AI and drug discovery have nothing to do with each other.
It’s a sharp contrast to the investments we’re seeing from top pharma teams who are increasingly using ML to accelerate their pipelines.
Watch the full conversation on our channel.
Is AI in drug discovery a wasted effort?
In this excerpt from Gradient Dissent, Martin Shkreli co-founder of DL Software, shares his controversial take on why he believes AI and drug discovery have nothing to do with each other.
It’s a sharp contrast to the investments we’re seeing from top pharma teams who are increasingly using ML to accelerate their pipelines.
Watch the full conversation on our channel.
